Structural Evidence for Effectiveness of Darunavir and Two Related Antiviral Inhibitors against HIV-2 Protease

Journal of Molecular Biology

Volumn 384, Issue 1, 2008, Pages 178-192

  Kovalevsky, Andrey Y ^a   Louis, John M ^b   Aniana, Annie ^b   Ghosh, Arun K ^c,d   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c PURDUE UNIVERSITY   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

aspartic protease; darunavir (TMC114); drug resistance

Indexed keywords

ANTIVIRUS AGENT; DARUNAVIR; GRL 06579 A; GRL 98065; IMIDAZOLE; PROTEINASE; UNCLASSIFIED DRUG; ZINC ACETATE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 2; HYDROGEN BOND; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INTERACTION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 54249109408     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.09.031     Document Type: Article

References (49)

1. Bock P.J., and Markovitz D.M. Infection with HIV-2. AIDS 15 (2001) S35-S45
2. Kanki P.J., and De Cock K.M. Epidemiology and natural history of HIV-2. AIDS 8 (1994) S85-S93
3. Humphrey J.H., Nathoo K.J., Hargrove J.W., Iliff P.J., Mutasa K.E., Moulton L.H., et al., & the ZVITAMBO Study Group. HIV-1 and HIV-2 prevalence and associated risk factors among postnatal women in Harare, Zimbabwe. Epidemiol. Infect. 135 (2007) 933-942
4. Soriano V., Gomes P., Heneine W., Holgiun A., Doruana M., Antunes R., et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J. Med. Virol. 61 (2000) 111-116
5. Barin F., Cazein F., Lot F., Pillonel J., Brunet S., Thierry D., et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS 21 (2007) 2351-2353
6. Marlink R., Kanki P.J., Thior I., Travers K., Eisen G., Siby T., et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265 (1994) 1587-1590
7. Matheron S., Pueyo S., Damond F., Simon F., Leprêtre A., Campa P., et al., French HIV-2 Cohort Study Group. Factors associated with clinical progression in HIV-2 infected patients: the French ANRS Cohort. AIDS 17 (2003) 2593-2601
8. Ariën K.K., Abraha A., Quiñones-Mateu M.E., Kestens L., Vanham G., and Arts E.J. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J. Virol. 79 (2005) 8979-8990
9. Sarr A.D., Sankale J.L., Gueye-Ndiaye A., Essex M., Mboup S., and Kanki P.J. Genetic analysis of HIV type 2 in monotypic and dual HIV infections. AIDS Res. Hum. Retroviruses 16 (2000) 295-298
10. Smith N.A., Shaw T., Berry N., Vella C., Okorafor L., Taylor D., et al. Antiretroviral therapy for HIV-2 infected patients. J. Infect. 42 (2001) 126-133
11. Rodes B., Holgiun A., Soriano V., Dourana M., Mansinho K., Antunes F., and Gonzalez-Lahoz J. Emergence of drug resistant mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J. Clin. Microbiol. 38 (2000) 1370-1374
12. Barlett J.A., DeMasi R., Quinn J., Moxham C., and Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 15 (2001) 1369-1377
13. Wlodawer A., and Vondrasek J. Inhibitors of HIV-1 protease: a major success in structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27 (1998) 249-284
14. Weber I.T., Kovalevsky A.Y., and Harrison R.W. Structures of HIV protease guide inhibitor design to overcome drug resistance. In: Caldwell G.W., Atta-ur-Rahman M.R., Player, and Choudhary M.I. (Eds). Frontiers in Drug Design and Discovery vol. 3 (2007), Bentham Science Publishers, International (UAE, USA, The Netherlands, Pakistan) 45-62
15. Damond F., Brun-Vezinet F., Matheron S., Peytavin G., Campa P., Pueyo S., et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistant mutations in HIV-2-infected patients treated with protease inhibitors. J. Clin. Microbiol. 43 (2005) 484-487
16. Rodes B., Sheldon J., Toro C., Jimenez V., Alvarez M.A., and Soriano V. Susceptibility of protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J. Antimicrob. Chemother. 57 (2006) 709-713
17. Ntemgwa M., Brenner B.G., Oliveira M., Moisi D., and Wainberg M.A. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 51 (2007) 604-610
18. Menéndez-Arias L., and Tözsér J. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol. Sci. 29 (2008) 42-49
19. Gustchina A., and Weber I.T. Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 10 (1991) 325-339
20. Chen Z., Li Y., Chen E., Hall D.L., Darke P.L., Culberson C., et al. Crystal structure at 1.9-Å resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV protease. J. Biol. Chem. 269 (1994) 26344-26348
21. Pieniazek D., Rayfield M., Hu D.J., Nkengasong J.N., Soriano V., Heneine W., et al. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 18 (2004) 495-502
22. Tong L., Pav S., Pargellis C., Do F., Lamarre D., and Anderson P.C. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures. Proc. Natl Acad. Sci. USA 90 (1993) 8387-8391
23. Mulichak A.M., Hui J.O., Tomasselli A.G., Heinrikson R.L., Curry K.A., Tomich C.-S., et al. The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J. Biol. Chem. 268 (1993) 13103-13109
24. Tong L., Pav S., Mui S., Lamarre D., Yoakim C., Beaulieu P., and Anderson P.C. Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere. Structure 3 (1995) 33-40
25. Priestle J.P., Fässler A., Rösel J., Tintelnot-Blomley M., Strop P., and Grütter M.G. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure 15 (2006) 381-389
26. Ghosh A.K., Chapsal B.D., Weber I.T., and Mitsua H. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc. Chem. Res. 41 (2008) 78-86
27. Koh Y., Nakata H., Maeda K., Ogata H., Bilcer G., Devasamudram T., et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) TMC-114 (UIC-94017) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47 (2003) 3123-3129
28. De Meyer S., Azijin H., Surleraux D., Jochmans D., Tahri A., Pauwels R., et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49 (2005) 2314-2321
29. Clotet B., Bellos N., Molina J.M., Cooper D., Goffard J.C., Lazzarin A., et al., POWER 1 and 2 Study Groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369 (2007) 1169-1178
30. Tie Y., Boross P., Wang Y.-F., Gaddis L., Hussain A.K., Leshchenko S., et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J. Mol. Biol. 338 (2004) 341-352
31. King N.M., Prabu-Jeyabalan M., Nalivaika E.A., Wigerinck P., de Bethune M.-P., and Schiffer C.A. Structural and thermodynamic basis for the binding of TMC-114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78 (2004) 12012-12021
32. Kovalevsky A.Y., Tie Y., Liu F., Boross P., Wang Y.-F., Leshchenko S., et al. Effectiveness of nonpeptidic clinical inhibitor TMC114 to highly drug resistant mutations D30N, I50V, and L90M of HIV-1 protease. J. Med. Chem. 49 (2006) 1379-1387
33. Kovalevsky A.Y., Liu F., Leshchenko S., Ghosh A.K., Louis J.M., Harrison R.W., and Weber I.T. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J. Mol. Biol. 363 (2006) 161-173
34. Amano M., Koh Y., Das D., Li J., Leshchenko S., Wang Y.-F., et al. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 51 (2007) 2143-2155
35. Brower E.T., Bacha U.M., Kawasaki Y., and Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem. Biol. Drug Des. 71 (2008) 298-305
36. Ghosh A.K., Sridhar P.M., Leshchenko S., Hussain A.K., Li J., Kovalevsky A.Y., et al. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J. Med. Chem. 49 (2006) 5252-5261
37. Wang Y.-F., Tie Y., Boross P.I., Tozser J., Ghosh A.K., Harrison R.W., and Weber I.T. Potent antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. J. Med. Chem. 50 (2007) 4509-4515
38. Desiraju G., and Steiner T. The Weak Hydrogen Bond in Structural Chemistry and Biology (2001), Oxford University Press, Oxford, NY
39. Nishio M., Hirota M., and Umezawa Y. The C-H/π Interaction. Evidence, Nature, and Consequences (1998), Wiley-VCH, New York, NY
40. Zhang Z.Y., Reardon I.M., Hui J.O., O'Connell K.L., Poorman R.A., Tomasselli A.G., and Heinrikson R.L. Zinc inhibition of renin and the protease from human immunodeficiency virus type 1. Biochemistry 30 (1991) 8717-8721
41. Ishima R., Torchia D.A., and Louis J.M. Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor. J. Biol. Chem. 8 (2007) 17190-17199
42. Otwinowski Z., and Minor W. Processing of X-ray diffraction data in oscillation mode. Methods Enzymol. 276 (1997) 307-326
43. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect D: Biol. Crystallogr. 50 (1994) 760-763
44. Potterton E., Briggs P., Turkenburg M., and Dodson E.A. Graphical user interface to the CCP4 program suite. Acta Crystallogr., Sect D: Biol. Crystallogr. 59 (2003) 1131-1137
45. Sheldrick G.M., and Schneider T.R. High resolution refinement. Methods Enzymol. 277 (1997) 319-343
46. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr., Sect A: Found. Crystallogr. 47 (1991) 110-119
47. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect D: Biol. Crystallogr. 60 (2004) 2126-2132
48. Esnouf R.M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr., Sect D: Biol. Crystallogr. 55 (1999) 938-940
49. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, San Carlos, CA